BriaCell Therapeutics has added UCLA Health Jonsson Comprehensive Cancer Center as a clinical site for its ongoing Phase 3 Bria-ABC trial (NCT06072612). This pivotal study is evaluating Bria-IMT™, the company’s lead immunotherapy candidate, in combination with a checkpoint inhibitor versus physician’s choice in patients with advanced metastatic breast cancer (MBC). Interim analysis is planned after 144 patient deaths, with overall survival as the primary endpoint.
This site addition signals BriaCell’s intent to accelerate enrollment in its most advanced clinical program. The company is banking on positive survival data from its earlier Phase 2 study, presented at ASCO 2025, to drive recruitment at this high-profile site. UCLA Health’s participation also lends credibility to the trial and may influence other major centers to join. The strategic importance of rapid enrollment is clear: faster data readout translates to earlier potential market entry in a competitive MBC landscape.
The choice of UCLA Health reflects a broader trend in oncology trials: leveraging established research networks with high patient volumes to overcome enrollment challenges. This approach, while potentially more expensive than activating smaller community sites, can significantly shorten trial timelines. It also reinforces the increasing concentration of clinical research within leading academic medical centers.
For BriaCell, partnering with UCLA Health carries both opportunities and risks. While the site’s patient pool offers access to diverse demographics and potentially faster recruitment, navigating the complexities of a large academic center can present administrative hurdles. Furthermore, UCLA Health’s reputation for rigorous research oversight will place added scrutiny on BriaCell’s trial conduct and data integrity.
The company’s projected 2026 data readout hinges on successful collaboration with UCLA Health and other participating sites. Key factors to watch include the rate of patient accrual at UCLA Health, the consistency of survival outcomes across different sites, and any potential safety signals emerging from the larger Phase 3 cohort. The outcome of this pivotal study will determine whether Bria-IMT™ can move beyond its promising early data and establish itself as a viable treatment option in advanced MBC. It will also test the hypothesis that personalized immunotherapy can meaningfully extend survival in this challenging patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
